UK AMR Diagnostics Collaborative: 
*Maximising the use of diagnostic technology to tackle AMR*

Fiona Carragher FRCPath  @DepCSOFiona
Deputy Chief Scientific Officer for England

*england.amrdiagnostics@nhs.net*

June 2018
The UK AMR Strategy: a tripartite approach

A One Health approach

- **PREVENT** infection prevention and control

- **PRESERVE** existing antibiotics through stewardship programmes that promote rational prescribing and **better use of existing and new rapid diagnostics**

- **PROMOTE** the development of new antimicrobials, new approaches and better **diagnostics**.

Underpinned by:
- Surveillance
- Research and Development
- Education, training and awareness
- International collaboration
The role of diagnostics in AMR

Independent review of Antimicrobial Resistance - Jim O’Neill

- Diagnostics are critical to the appropriate use of antimicrobials
- Step change in the way technology is incorporated into the decision making process
- Currently many decisions are based on an empirical diagnosis
- Rapid point of care diagnostics enabling a precise, timely diagnosis
- Decision support approach to drive change in prescribing

“I call on Governments to ensure that, by 2020, all antibiotic prescriptions will need to be informed by .... a rapid diagnostic test wherever one exists” Jim O’Neill

“Having rapid, low-cost, and readily available diagnostics is an essential part of the solution to this urgent problem.” Dr Margaret Chan, DG, World Health Organisation
Diagnostics – the signalling system for the NHS

• Direct patients and patient flows so that the right people get to the right place at the right time

• Ensure treatment and management is efficient, effective and coordinated

• Have a critical role in prioritising activity so that services are resilient and sustainable

• Fundamentally shape the health economics of particular patient pathways
Which diagnostics could be used in AMR?

- Bacterial or viral
- Bacterial type
- Resistance *(which antibiotics *must I not* use?)*
- Susceptibility *(which antibiotics *can I use?)*

Recognising there is also a role for host response biomarkers

National ambitions

1. Halve gram –ve HCAI blood infections by 50% by 2020
2. Halve inappropriate prescribing in humans by 2020
3. Reduce animal antibiotic use to 50mg/kg by 2018
4. Work internationally to bring new products to market

- Infection control
- Optimised prescribing
- Diagnostics
- Improved animal use

- Education & training
- Surveillance, behaviour & evidence-based interventions
- New approaches through discovery, innovation & global action
UK AMR Diagnostics - Vision

…..“This strategy will tackle the issues around AMR through patient-centred, cost effective diagnostics by ensuring that the right test is available at the right place at the right time.

“It will maximise the use of available technologies in human & animal health sectors in the most appropriate settings.”

The vision will be delivered through a coordinated & consistent national approach to standards & practice

- In every part of the country, in every healthcare setting, the same level of access to rapid diagnostic technology & digital antimicrobial guidance tools are available

- The technology meets nationally set standards of quality & response times

- There is recognition that different settings might need different technical solutions

- Services are flexible & responsive to the adoption of new technologies that will provide continuous improvement
UK AMR Diagnostics – Strategy

Ensuring that the right test is available at the right place at the right time.

- Self-care & monitoring
- Pharmacy & other high street services
- Primary and Community Care
  - We need to capture good practice examples
  - Linked to changing behaviours and targeted education and training
- Secondary and Tertiary Care
- Public health & surveillance
  - Linked through integrated data-sharing
  - Coordinated by coherent commissioning
Diagnostic challenges – current landscape

- Lack of clinical trial data and cost effectiveness assessments.
- The need to avoid the inappropriate use of tests. There are many clinical scoring tools based on symptoms and signs that can be used to rule in or rule out infection.
- Collecting the outcome of tests to inform national and local data collections
- If tests do not have cost benefit or adequate performance characteristics in the patient population under investigation they have potential to do harm.
- Rapid adoption of new technology - change behaviours around the use of tests.

How do we value diagnostic tests in the context of their contribution to the prevention of the growth of resistance?
Diagnostic challenges – specific tests

• The right setting – *different settings might need different technological solutions*

• Meeting quality standards - *including response time*

• Personal to the needs of the patient - *their symptoms, healthcare system, behaviours and social setting, supporting shared decision making*

• Place in the care pathway – *diagnostic strategies*

• Clinical judgement – *supporting, not replacing*
UK AMR Diagnostic Collaborative Programme

KEY AREAS OF FOCUS

SYSTEM PARTNERS

Public Health England

Health Education England

DEFRA
Diagnostic stewardship- definition

- Coordinated professional guidance and interventions to improve patient understanding, care and management through the appropriate use of clinical assessment and clinical scoring algorithms, biomarker tests and/or microbiological diagnostics to guide therapeutic decisions or screening strategies.

- It should promote appropriate, timely diagnostic testing, including specimen collection, and pathogen identification and accurate, timely and audited reporting of results to guide care. It should discourage unnecessary diagnostic testing and the use of tests that yield misleading results.

- Diagnostic Stewardship should utilize microbiological data, including accurate and representative AMR surveillance data to inform local treatment guidelines, and AMR control strategies, and should be an integral component of measures to improve antimicrobial stewardship and infection prevention and control.

WHO 2016: Diagnostic stewardship
A guide to implementation in antimicrobial resistance surveillance sites
Diagnostics as part of the multi-professional approach
‘a seamless partnership between laboratories, pharmacists and clinicians’
UK AMR DC 18/19 areas of focus
-Diagnostic Stewardship

- Use of biomarkers eg CRP/Procalcitonin in acute settings or as POCT in the community
- Quality improvement approach to diagnostics within the sepsis pathway enabling timely review of antibiotic therapy
- Urinary infections: Tackling inappropriate use of urinary diagnostics particularly in the frail elderly population #ToDipOrNotToDip and focus on the urine culture pathway

UK wide building on good practise, driving quality improvement and addressing variation
Innovation - opportunities through new diagnostics

**Handheld ‘lab on a chip’**

Coupling smartphones with ‘lab on a chip’ technology for tests egg gene arrays
Still at research stage but show great potential

**Point of care testing**

Well established for indirect technologies such as CRP testing.

*Developments in microarrays offer increased potential for direct testing*

**High throughput genomic technologies**

Delivers rich direct testing, allowing detailed identification & surveillance
Seeing advances in speed of test and reduction in cost
Integration and collaboration is everything

Academia

NHS

Industry

Patients

International

Area of maximum advance

INVENTION  EVALUATION  ADOPTION  DIFFUSION
The system must be responsive

The work of the UK AMR diagnostic collaborative is crucial in ensuring that all the right groups and agencies are working together to address these challenges.

- **Connected data** across care pathways
- **Systematic approach to rapid adoption**
- **Streamline & develop evidence base**
- **Prioritise technologies**
- **Supportive regulatory structure**
The power of diagnostics in AMR: opportunities and challenges

Opportunities

- Transforming existing pathways and approaches to support new models of care
- Unpicking commissioning of diagnostics to focus incentives
- Quality of data available about current use of diagnostics and outcomes
- Constant evolution of AMR requiring ongoing innovation to keep up
- Next-gen diagnostics offer a precise, timely diagnosis – allowing the use of the right drug in the right place at the right time
- New settings for diagnostics utilising point of care testing and multi-professional teams
- Commissioning levers such as CQUIN, to drive uptake of new approaches

Challenges